Want to see AU:TRP full AI Analyst Report?
TRP Stock Chart & Stats
AU$0.08
<AU$0.01(3.61%)
At close: 4:00 PM EDT
AU$0.08
<AU$0.01(3.61%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.48
Previous CloseN/A
Volume60.60K
Average Volume (3M)88.85K
Market Cap
AU$5.44M
Enterprise ValueAU$1.28
Total Cash (Recent Filing)AU$8.29M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,464,844
10 Day Avg. Volume113,029
30 Day Avg. Volume88,853
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.69
Price to Sales (P/S)10.80
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt limits interest obligations and refinancing exposure, preserving financial flexibility while the company funds development. Although equity has declined, a debt-free structure reduces fixed-claim pressure and provides a more resilient base than a similarly loss-making, highly leveraged business.
Evidence Of Earlier Revenue GrowthEarlier revenue expansion indicates the business has demonstrated some ability to generate commercial growth rather than remaining entirely stagnant. That history may support future recovery if products or activities regain traction, although the sharp 2026 decline shows this strength has not yet become consistent.
Cash Losses Broadly Reflect Reported LossesCash outflows broadly tracking reported losses suggest the weak earnings picture is visible in cash generation rather than being driven mainly by unusual non-cash charges. This alignment improves the interpretability of results and clarifies the funding required to reach sustainable operations.
Bears Say
Sharp Revenue ContractionA revenue decline of this magnitude weakens operating leverage and makes it harder to support research, commercial execution, and administrative costs. It also shows that earlier growth has not translated into a stable demand base, increasing the risk that future results remain volatile and dependent on renewed revenue generation.
Persistent Unprofitable OperationsOngoing losses and gross profit turning negative indicate that the current cost structure is not scaling with revenue. Continued operating deficits can consume capital before the business reaches profitability, while worsening margins reduce the ability to reinvest internally and make sustainable earnings increasingly dependent on future funding.
Increasing Cash Burn And Capital ErosionRising operating cash burn alongside a materially smaller equity base points to sustained funding needs and weakening financial endurance. Even without debt, continued losses can erode the capital available for development and operations, increasing execution and runway pressure over the coming periods.
Tissue Repair Ltd News
TRP FAQ
What was Tissue Repair Ltd’s price range in the past 12 months?
Tissue Repair Ltd lowest share price was AU$0.06 and its highest was AU$0.48 in the past 12 months.
What is Tissue Repair Ltd’s market cap?
Tissue Repair Ltd’s market cap is AU$5.44M.
When is Tissue Repair Ltd’s upcoming earnings report date?
Tissue Repair Ltd’s upcoming earnings report date is Mar 04, 2027 which is in 160 days.
How were Tissue Repair Ltd’s earnings last quarter?
Tissue Repair Ltd released its earnings results on Aug 31, 2026. The company reported -AU$0.053 earnings per share for the quarter.
Is Tissue Repair Ltd overvalued?
According to Wall Street analysts Tissue Repair Ltd’s price is currently Overvalued.
Does Tissue Repair Ltd pay dividends?
Tissue Repair Ltd does not currently pay dividends.
What is Tissue Repair Ltd’s EPS estimate?
Tissue Repair Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tissue Repair Ltd have?
Tissue Repair Ltd has 60,464,844 shares outstanding.
What happened to Tissue Repair Ltd’s price movement after its last earnings report?
Tissue Repair Ltd reported an EPS of -AU$0.053 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tissue Repair Ltd?
Currently, no hedge funds are holding shares in AU:TRP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tissue Repair Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
AU:TRP Sentiment 50%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tissue Repair Ltd
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing recovery following cosmetic procedures. Its product pipeline features TR-987 and a suite of innovative dressings and matrices, including the proprietary Glucoprime technology. These are specifically engineered to address challenging conditions such as chronic wounds, burns, and other complex dermal injuries. Additionally, TR Pro+ is being developed for post-procedure care after minimally invasive aesthetic treatments. Beyond these core programs, Tissue Repair is also exploring applications in animal health, novel bandage and scaffold technologies, and various other therapeutic areas. The company was founded in 2012 and operates from its headquarters in Sydney, Australia.
Technical Analysis
Acrux
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―